Can someone explain what this is? Thanks.
ORDER GRANTING CONFIDENTIAL TREATMENT:
Oncothyreon, Inc. submitted an application under Rule 24b-2 requesting
confidential treatment for information it excluded from the Exhibits to a Form 10-Q filed
on November 5, 2015.
Based on representations by Oncothyreon, Inc. that this information qualifies as
confidential commercial or financial information under the Freedom of Information Act,
5 U.S.C. 552(b)(4), the Division of Corporation Finance has determined not to publicly
disclose it. Accordingly, excluded information from the following exhibit will not be
released to the public for the time period specified:
Exhibit 10.1 through November 5, 2018
For the Commission, by the Division of Corporation Finance, pursuant to
@tgtxdough @SheffStation picked up more $onty here
RT @tgtxdough: @SheffStation RJ $ONTY believe ONT-380 could gain a sizeable portion of $800 million third-line HER2+ metastatic breast CA …
@SheffStation RJ $ONTY believe ONT-380 could gain a sizeable portion of $800 million third-line HER2+ metastatic breast CA market in U.S
@SheffStation Sheff $ONTY 3 weeks away I added today 3.10 IMHO interesting play into the data. Cowen expecting data on 30PTs.
Yes. Anything between now and San Antonio Conference is just noise. The IBB was down 1.6% today, we were down a little more but with a $3 stock pennies make big percentages. I'm still thinking $5 post S.A.
I've seen your posts over at Investors Village. Lots of non believers over there.
Wow, 3 short days ago, chart looked great, everything in line for a move up and she collapsed. A biotech is a biotech is a biotech. Most every article is positive on 380, things look very good. But boy, is there downward pressure on the pps.
I do hope things turn around for you. The cheap dart-board rag you keep tooting will be your finish, if you take their investment advice.
Put your real Googles on and do some real research
In the meantime someone is dumping a lot of shares and she looks a little sick right now. Making this long very nervous.
Thanks - helpful. If data at SABS are supportive and lead to expedited 2/3 study for CNS, $5+ seems like a layup. With positive CNS data I see sale to Roche or Pfizer at $11 in Q1. $1.5B less $250M to Array, distributed to 115M shares (after BVF warrant exercise) I also think this is the reason planned JV of protocell product was delayed.
With numerous upside scenarios from the upcoming clinical data at SABCS that could help justify/solidify a direct, expedited path for potential approval for the ONT-380/Herceptin/Xeloda triplet in the HER2+ patient population and/or the ONT-380/T-DM1 combo treatment in the brain metastases patient group, I view Oncothyreon as an attractive name at currently levels. I think Oncothyreon can easily reach $3.75-$4.00+ before SABCS data (though volatility should be expected), and I believe either notable overall response rate improvement for the ONT-380/T-DM1 data or continued display of promising efficacy trends in the brain metastases patient group have the potential to trigger investors to justify a $5+ price per share (an enterprise value of approximately $425 million).
They increased their position "as shares declined" 24.31%. Clearly, they were accumulating shares that they believe were undervalued.